Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

March 15, 2023

OTC Pink Market US Health Care Biotechnology earnings 40 min

Earnings Call Speaker Segments

Brant Biehn

executive
#1

Good afternoon, everyone, and thanks for joining us on today's call. With us from Vaxart are our Chief Executive Officer, Andrei Floroiu; our Founder and Chief Science Officer, Dr. Sean Tucker; our Chief Medical Officer, Dr. James Cummings; and our Chief Financial Officer, Phil Lee. Ahead of beginning, I want to remind all of you that on this conference call, forward-looking statements may be made by Vaxart, which include statements regarding the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. A number of important factors could cause actual results to differ materially from those discussed in these forward-looking statements, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. No obligation is undertaken by Vaxart to update any forward-looking statements after the date of this call. I'll now turn the call over to Andrei Floroiu. Andrei?

Andrei Floroiu

executive
#2

I appreciate that, Brant, and I want to thank everyone for being here with us today. We're glad to walk you through an update on our corporate strategy and discuss the path forward for our transformational oral vaccine platform. As we stated in the press release that went out this afternoon, we're putting priority on developing our oral pill bivalent norovirus vaccine candidate, since we see this as the strongest approach for positioning Vaxart for long-term success and maximizing shareholder value. What this strategy aims to do is direct the bulk of our investments toward the programs that hold the greatest near-term potential for validating and advancing our oral pill technology platform. Norovirus is a very appealing target for Vaxart, given the highly compelling risk-reward profile of our program. I'd like to emphasize five dimensions here. Those are the disease characteristics, the large commercial opportunity, the attractive competitive context, the compelling data we've generated thus far, and our near-term data readouts. So first, the key characteristics of norovirus and some infectious disease remain unchanged from when we began working on our program, and we don't anticipate that changing; that stands in contrast to COVID, which has been a perpetually shifting target with emerging variants. Norovirus is also less difficult for a company such as Vaxart to develop a solution for. Second, the commercial opportunity in norovirus is enormous for a company of any size. There's a yearly $10 billion disease burden in the US by itself, along with an estimated $60 billion burden worldwide. Third, competition in the norovirus vaccine space is quite limited. No vaccine has been approved anywhere in the world, and as far as we're aware, ours is the only oral program under development. To our knowledge, just one other advanced program is in development. Importantly, when compared with potential injectable alternatives, our oral enterically delivered mucosal vaccine could offer significant advantages for an enteric mucosal infection. On top of that, an oral pill vaccine brings inherent convenience advantages across both key populations, kids and the elderly. The fourth point is that the data we've generated so far in our norovirus program is substantial and quite compelling; we've finished six clinical trials, enrolling 360 subjects in our norovirus program; and that figure doesn't include the two ongoing Phase II trials, with top line data expected to read out this year. The immunogenicity data we've observed to date from the completing trials appears consistently strong, and the safety and tolerability data so far is benign. Moreover, as my colleagues will cover in greater detail, our data in one key segment, the elderly, appears much better than what we'd anticipate in this population, which differs from the data that has been seen with injectables. So we have plenty of concrete data points here that make us very excited about the potential for clinical success in our norovirus program. We'll be highlighting many of these aspects over the coming months at both scientific and investor events. So, we have two significant top-line data readouts coming up within the next six months. The first is our Phase II dose-ranging study in mid-2023. The second is our Phase II challenge study in the third quarter. Beyond those, and this is important, we think that if the data coming out of our norovirus program keeps being strong, we'll have a variety of value-creating paths for moving that program ahead. Mid to late-stage vaccine assets that address large markets are extremely appealing to a lot of industry players; and these kinds of vaccine assets are fairly uncommon, which explains why at JPMorgan this year, we saw so much interest in assets of this type. So we think this industry dynamic will turn into valuable optionality for us down the road. Now let me spend a little time on our COVID-19 program; we still believe the current injectable COVID-19 vaccines leave much to be desired, and that the encouraging data from our program indicates our platform could fundamentally change the way we fight COVID-19 and pandemics more broadly. That said, we've had to adapt our strategy to the ongoing evolution of the COVID-19 pandemic and the shifting perspective of key stakeholders, such as governments and regulators. As a result, we chose to play to the strength our clinical data suggests and concentrate on addressing pandemic preparedness by developing a pan beta coronavirus steps. A notable weakness of injectable COVID-19 vaccines has been their relatively narrow strain-specific activity, whereas cross-reactivity has been a characteristic of our mucosal oral feel vaccine. Vaxart activity will be crucial for delivering better protection against a virus that keeps evolving rapidly and may scale the protection afforded by currently approved vaccines. So our broader focus on this better coronavirus approach means we won't move forward with the previously planned clinical COVID-19 trials. And as we advance new vaccine candidates, we'll figure out the best development plan going forward. In addition, we remain engaged in discussions with regulatory agencies, governments, non-governmental organizations and other strategic partners to maximize the value of all our vaccine programs, and we'll provide updates as warranty. While we deeply value every member of the Vaxart team, we've taken the difficult but necessary steps to adjust our staffing levels with a 27% reduction in workforce, to reflect these new priorities and activities; with the change in program prioritization our cash runway now extends into the second quarter of 2024. And as James will discuss shortly, we expect to achieve several important milestones within the Norovirus program between now and then. These milestones have the potential to support the continued advancement of the Norovirus program towards the Phase 3 trial, while also providing further validation of the promise of our oral pill vaccine platform. I'm excited to let you know that, to highlight both our Norovirus program, which is differentiated, and our bivalent candidate, we'll be holding a virtual key opinion leader call. That call is set for March 28 at 1:00 P.M. Eastern Time, and joining it will be a number of leaders in the development of Norovirus vaccines. Among them are Sara Sarah Bartsch, who serves as PHICOR Project Director at the Research Foundation of The City University of New York, and Jan Vinjé, who heads the National Calicivirus Laboratory at the Centers for Disease Control and Prevention in Atlanta. They'll offer their insights and perspectives regarding the worldwide need for a Norovirus vaccine that is safe, effective, and readily deployable. With that said, I'll hand the call over to James so he can review our Norovirus program.

James Cummings

executive
#3

Andrei, thank you. I feel a great deal of enthusiasm for what our oral Norovirus vaccine program might accomplish — it has the ability to reshape how vaccination is approached worldwide, delivering meaningful benefits over vaccines given by needle. In our Phase 1 Norovirus clinical trials, covering both younger adults and elderly groups, we have already shown strong immunogenicity results. According to those results, our bivalent candidate generated a powerful immune reaction, including an IgA antibody-secreting cell response rate of 78% against the GI.1 strain and 93% against the GII.4 strain, and we saw no interference. In other words, GI.1 antigens being present did not block immune stimulation directed at the GII.4 strain, and the reverse also held true. Equally important, our Norovirus candidate so far in trials shows a favorable safety profile — it has been well tolerated, with zero serious adverse events — and this matches what we see across our platform. We think it may also lower transmission. As our press release this afternoon noted, one central element of how we are prioritizing the Norovirus vaccine program is broadening the currently running Phase 2 GI.1 Norovirus challenge study by adding more challenge cohorts. Our view is that the larger data set these extra cohorts produce will raise the odds of finding a correlate of protection linking immune responses to the vaccine with a decreased risk of Norovirus infection, or acute gastroenteritis. If such a correlate of protection can be identified, it could shrink both the size and the duration of a Phase 3 trial. Once those additional cohorts are included, our expectation is to report top line data from the Phase 2 challenge study during the third quarter of 2023. Last month, as we announced, we began and dosed the first subject in the Phase 2 dose-ranging study of our bivalent norovirus vaccine candidate — an essential next step toward moving this promising candidate into a Phase 3 clinical study. Our bivalent vaccine is intended to go after the prevalent strains from two norovirus genotypes, G11 and G24. Those are responsible for most norovirus disease in humans. Our oral pill bivalent norovirus candidate stands apart from other norovirus vaccines in development for the reasons Andrei already mentioned. It produces immune responses both mucosally and systemically. We are tailoring the presentation for different age groups. Refrigeration isn't required, since it remains stable at room temperature, and distribution becomes far simpler, while also removing the biomedical waste that comes with giving injected needle-based vaccines. The Phase 2 dose-ranging trial is anticipated to enroll roughly 135 million healthy adults across three sites in the United States. The initial 10 subjects got open-label high-dose vaccine, and the rest will be randomized to high-dose vaccine, low-dose vaccine, or placebo. Every vaccine arm will contain 50 subjects, while the placebo arm will contain 25 subjects. Safety and immunogenicity serve as the primary endpoints, which will let us set a dose level for Phase 3 development. We expect to report top-line data from the Phase 2 dose-ranging study in mid-2023. Should that work out, we would move on to a Phase 2b trial, which would then bring us to an end of Phase 2 meeting with the FDA in the coming year. Beyond the studies already running that test our norovirus vaccine candidates in healthy adults, we plan to launch a clinical trial funded by the Bill & Melinda Gates Foundation. That trial would assess whether our norovirus vaccine candidate can prompt breast milk antibodies and pass antibodies along to infants who are breast-feeding. Should that passing along happen, it might offer a key way to shield infants against norovirus infection. That matters a great deal, since norovirus infection shows up so often in young children. Our plan is to get this study started in 2023. Given the data we keep accumulating and the trials now in progress, we think our bivalent norovirus candidate could take a potentially speedy route toward submission and possibly gain FDA approval. We are eager to push forward this promising norovirus vaccine candidate, which could help people, communities and health systems around the world. I'll hand the call to Sean now so he can update us on our novel COVID-19 constructs. Sean?

Sean Tucker

executive
#4

Thank you, James. It looks like the SARS-CoV-2 pandemic is shifting — possibly settling in as an endemic virus — but the virus is still producing meaningful mortality or morbidity and it keeps mutating. Because of that, a real and continuing danger remains that fresh variants will appear and that today's vaccines will only offer limited protection against those viral threats. Regulatory guidance and the commercial opportunity, as we know, are both still changing. Given how much time it takes to develop, manufacture and, naturally, administer that vaccine, we think pursuing the newest variant isn't the optimal approach for any company or for society. So we're now working on novel constructs that might deliver protection both against the SARS-CoV-2 strains that dominate at present and against strains yet to come. In our view, this more proactive strategy will be crucial to escaping the hamster wheel of COVID-19 vaccine development, to bringing the pandemic under control and to lessening the individual and societal burdens of an endemic infectious disease. What's more, drawing on the substantial mucosal cross-reactivity data reported so far from the Phase 1 and Phase 2a studies of our COVID-19 vaccine candidate, we think there's a possibility we could create an oral pan-betacoronavirus vaccine. SARS-CoV-2, the virus responsible for COVID-19, is a sub-thesis of virus inside the betacoronavirus genus, just as other coronaviruses are; a pan-betacoronavirus vaccine would make future-proofing a vaccine simpler, whether the emerging coronavirus threat involves a new SARS-CoV-2 variant, SARS-CoV-1, MERS-CoV or another betacoronavirus. Bear in mind that our clinical data for COVID-19 showed it's possible to employ antibodies at the entry points for SARS-CoV-2 infection, the nasal and oral mucosa. Those mucosal antibodies proved cross-reactive to multiple SARS-CoV-2 strains and to more distantly related betacoronaviruses too, including SARS-CoV-1 and MERS-CoV. It's worth noting that SARS-CoV-1 and MERS-CoV killed more people than SARS-CoV-2, and a future betacoronavirus infection might likewise be more dangerous. So we believe a mucosal antibody inducing the pan-betacoronavirus vaccine could be a valuable tool for pandemic preparedness. I'll now hand the call to Andrei. Andrei?

Andrei Floroiu

executive
#5

Appreciate that, Sean. At this point I'd like to briefly extend a welcome to Phil Lee, who has stepped in as Vaxart's Chief Financial Officer. Phil came aboard back in December, and he carries close to 15 years of background in strategy, M&A and partnering work spanning transactions worth over $20 billion. On behalf of all of us on the leadership team, it's great to have him with us. Phil?

Phil Lee

executive
#6

Appreciate that, Andrei. A summary of how we performed financially across the whole of 2022 appears in the press release issued today. At the close of the year, Vaxart held cash, cash equivalents, restricted cash and marketable securities totaling $95.7 million, which compares with $114.8 million on September 30, 2022. That decline stemmed mainly from the cash we spent on operations while moving our norovirus program forward. As Andrei mentioned before, this funding gives us cash runway extending into the second quarter of 2024. At this point I'll hand the call back to Andrei so he can offer his closing remarks.

Andrei Floroiu

executive
#7

Thanks, Phil. With the growth of our Phase 2 GI.1 norovirus study and the launch of our Phase 2 bivalent norovirus study, we're entering 2023 with considerable momentum. Our positioning is very strong when it comes to producing the data we think will be necessary to shape a Phase 3 clinical trial capable of backing approval for our bivalent norovirus vaccine candidate. Beyond that, given the portfolio prioritization update we shared today, we're confident we now have the right strategy and the resources to put ourselves on a path toward success and lasting sustainability. Prioritizing our norovirus program will additionally give us a number of significant milestones that investors can use to gauge our progress. Among these milestones: sharing top line data in mid-2023 from the ongoing Phase 2 dose-ranging study of our bivalent norovirus vaccine candidate. Sharing top data in Q3 2023 from the ongoing Phase 2 channel study for our G11 monovalent norovirus vaccine candidate. And launching in 2023 a Bill & Melinda Gates Foundation-funded clinical trial to assess how well our norovirus vaccine candidate can induce antibodies in breast milk and pass antibodies along to young infants. Last, as I noted before, on March 28 at 1:00 p.m. Eastern time we'll hold a virtual key opinion leader call demonstrating what sets our norovirus program and our bivalent vaccine candidate apart. We're hoping you'll be with us for this exciting and informative virtual event. On behalf of Vaxart's leadership team, I want to thank you for your time today, and we're now glad to take your questions.

Charles Duncan

analyst
#8

Hello, and good afternoon to you, Andrei, along with the rest of the team. We appreciate you fielding our question. I like the attention being given to norovirus, and I had a few things I wanted to ask on that front. Regarding the topline data expected in the middle of 2023, I suppose what I'm curious about is whether you might describe what you'd hope to observe — perhaps without getting too deep into numbers — specifically what would give you confidence when it comes to bringing that data set before the agency? Also, would you expect that end of Phase 2 meeting to happen by the close of 2023, or during 2024 — I believe you mentioned early 2024 — yet might you be able, contingent on funding, to get a Phase 3 up and running at around this same point next year?

Andrei Floro

analyst
#9

James, would you like to handle this one?

James Cummings

executive
#10

Certainly. Thank you, Charles. I appreciate the question. So regarding the topline data from the Phase 2 dose confirmation dose ranging study, the topline results that we will have in mid-23 come from 135 individuals, correct — each one either getting placebo or a higher or low dose of our bivalent construct. What I'd say is that with those reports, we are seeking the immunogenicity along with the safety profile of the product. As before, with our platform, a very consistent clean safety profile has been observed; and we will see how that data looks when midyear arrives. As for our strategy with the agency, and when an end of Phase 2 study might happen: once we have the results from that topline data, we will be putting together the follow-on study — Part B of that study — which will provide us the numbers required to go before the FDA. That would likely be — well, I won't get into how big it is in detail, but it would be a study of larger size determined by the dose selected; and I could see that potentially occurring in 2024. Does that address your question, Charles?

Charles Duncan

analyst
#11

Yeah, I believe that's right. We're eager to see those results. For my next question, it's directed at either Andrei or Phil. Phil, you've come aboard the company not long ago, so I'm curious whether you might share additional detail regarding our R&D expenditures, which I believe came to roughly $81 million across the year. Of that total, how much related to COVID as opposed to noro? And regarding the R&D spending you expect during the current year, what share goes to COVID versus noro, keeping that same sequence in mind?

Andrei Floroiu

analyst
#12

Phil, would you like to give that a try?

Phil Lee

executive
#13

Absolutely. I'd say the clearest route to those figures is really through the 10-K we submitted. In that document, we reported the external spend tied to norovirus and COVID. As for what lies ahead, clearly there's been considerable emphasis on norovirus and the trials — the clinical trials we currently have underway. So you can broadly assume that most of our spending will go toward norovirus, even though we're also advancing other assets within our platform.

Charles Duncan

analyst
#14

All right, that helps. One last thing about partnering. My question, I suppose, concerns strategy. It likely won't be a perfect question, and of course an answer requires two parties. But when it comes to advancing into a bigger, later-stage Phase 3 trial in noro, do you expect data still this year that would let you move ahead with partner talks, or would you prefer to carry a candidate into Phase 2 on your own? Thanks.

Andrei Floroiu

analyst
#15

Hi Charles; I'll take a shot at responding, though as you know, it's somewhat early for that; I believe the results coming in the third quarter, especially the Challenge results, are regarded as highly significant by investors as well as possible strategic partners. So once those results arrive, that will be a crucial decision point for us regarding our next steps.

Charles Duncan

analyst
#16

Understood. That helps. I appreciate you fielding my questions.

Andrei Floroiu

analyst
#17

Many thanks Charles.

Mayank Mamtani

analyst
#18

Good afternoon everyone. I appreciate you answering our questions, and I also value the prompt shift in emphasis toward norovirus. So, building perhaps on what was just said. Andrei, might you elaborate a bit further on the Challenge study, the reasoning behind larger cohorts? And I believe it would aid investors to grasp which degrees of protection, whether asymptomatic efficacy or perhaps transmission, you aim to hit in this dataset? And if you could go somewhat further into which immune correlates you are examining, that too would be quite useful?

Andrei Floroiu

analyst
#19

So James, would you like to field this one?

James Cummings

executive
#20

Certainly. So Mayank, I appreciate the question. Regarding the sort of data to examine in detail for what we are evaluating in the challenge study, basically we are evaluating protective efficacy, meaning a reduction in symptomatic acute gastroenteritis caused by norovirus. We are additionally evaluating the possibility of a decline in shedding, viral shedding of norovirus; we all recognize that only a small amount of norovirus is needed to trigger an infection. Yet if you are able to reduce shedding, you ought to reduce possible transmission. So those are two items we are evaluating. And then one more aspect of that study, specifically, is examining a correlates of protection. We believe that a correlates of protection could be crucial in gauging the scale of our Phase 3 efforts and assessing the possibility of reducing numbers and/or time lines, for a Phase 3 study examining a correlates of protection. This challenge is a G11 challenge. And our bivalent, I believe, which we refer to as the dose-ranging study, has G11 and G24; so we are quite interested in how that correlates of protection might appear, and then providing that to the FDA in discussions to gain a sense of how that could affect our Phase 3 study. Is that what you were asking about?

Mayank Mamtani

analyst
#21

Yes, that covers it. And perhaps, if I may — could you go into somewhat greater detail regarding the dose-ranging trial for the bivalent? The dose levels under consideration — how should we view those relative to the monovalent effort you've previously conducted? And what kinds of findings are you hoping to obtain there that you believe would prove quite useful in conversations with regulators? Also, if a bivalent-specific challenge study is required before launching a Phase 3, might you make that clear? Thanks once more for fielding the question.

James Cummings

executive
#22

Absolutely. Thank you. Regarding the dosage levels in that trial, and it can be found on clinicaltrials.gov, we're evaluating a bivalent of G11 and G24 at 5:10 <<inaudible>>, for which the total dose comes to 1:11, correct? As for the high dose, that involves G24 and G11, amounting to 1:11 for each strain, giving a total dose of 2:11. In earlier trials of ours, doses have reached as much as 1:11. Thus this represents a greater dose, and as I mentioned, our aim will be to preserve what we've already observed throughout our doses in these other vaccines, namely a clean safety profile. Concerning other diarrheal illnesses or how diarrheal disease presents while conducting trials prior to entering our Phase 3, naturally, we would gather any data during a Phase 2 should someone develop acute gastroenteritis, though that would be exploratory in nature only; such trials aren't truly designed for that; that's precisely where our Phase 3 trial would fit in; so I believe the optimal approach is to capitalize on what might be the advantage of our challenge study. As you're aware, among adult populations, transmission doesn't occur consistently each year; it's instead driven by selected populations; therefore we would eagerly anticipate gaining substantial insight from that challenge study concerning possible protective efficacy. Does that address the question, Mayank?

Mayank Mamtani

analyst
#23

Yeah, that covers it. Perhaps just one additional item. Could you speak as well to what's needed for you to get the breast-feeding mothers and infant study underway? And could you give us a quantitative sense of how much money you've got or will get from the Gates Foundation?

James Cummings

executive
#24

Well, the funding side I'll hand over to the folks who practice those crafts; but as far as I'm concerned, that investigation in lactating postpartum women, in which our oral tableted vaccine would be administered to women who've already given birth, meaning they have infants they're breast feeding, is designed to measure a couple of things; first, obviously checking to make sure we're safe, but also checking how much antibody shows up in the breast milk. That, I believe, matters a great deal, and it's one component of this study. Then the other component involves measuring the quantity of antibodies directed at norovirus that we detect in the infants' faeces or stool. So examining the passage, or transfer, of those antibodies present in breast milk, I think, is quite important. And as we see it, this could be a means of safeguarding some of the most vulnerable populations through a vaccination strategy administered to the lactating mom. The matter of dollar amounts, and so forth, I'll leave to other people on the call. Andrei, Sean, Phil, would any of you like to weigh in?

Andrei Floroiu

analyst
#25

Yeah, so Mayank, regarding the dollar figure, we won't be giving specifics. All we've stated is that this trial was co-founded by the Gates Foundation and us. And that's all we're going to say about it.

Brant Biehn

executive
#26

Great. Yeah, we have several questions that came in online. I'll get us started. Andrei, this one's directed at you. The question asks why norovirus is the priority, why we're making that call at this point, and why we didn't make it sooner? Andrei.

Andrei Floroiu

analyst
#27

Yes, and thank you, Brant. We genuinely think we hold one of the top norovirus vaccine candidates out there, and that point deserves emphasis. Our choice to zero in on the norovirus program came after a thorough strategic look at our business and a review of every candidate in our pipeline, which included examining what would get us to a commercial product fastest, plus the most efficient route to making the most of the resources we have now. So the reason norovirus got priority is that, on the whole, it offers us the strongest risk-reward profile in the near term. As we said, two very significant data readouts are coming this year, one at midyear and one during the third quarter. And we do view moving the norovirus program forward, or advancing it, as the optimal approach for validating our program and our platform and for putting us in position for long-term success. And importantly, the revised cash runway stretches well past those two data readouts; so I believe investors should be aware of that.

Brant Biehn

executive
#28

Great. Thank you, Andrei. So turning to the cash runway, there are quite a few questions about norovirus. Even so, this one is for you; and every one of them has to do with norovirus — let me try to sum up the full scope of what we're being asked. So is it possible to finish a Phase 3 study in norovirus without raising more money? What is the anticipated cost and length of a Phase 3 study? And is a Phase 3 study covered by your cash runway? Phil, I'll hand that to you.

Phil Lee

executive
#29

Okay, thank you, Brant. Our cash runway projection stretches to Q2 2024. That figure accounts for expenses tied to every one of our current norovirus Phase II trials, plus the study backed by the Gates Foundation that we intend to launch later this year. What it leaves out is the anticipated expense of running a Phase 3 trial, and right now we aren't offering any estimate regarding what such a Phase 3 trial might cost.

Brant Biehn

executive
#30

Great. I appreciate that, Phil.

Phil Lee

executive
#31

Thanks to you as well, Brant. James, this next one concerns norovirus and is directed at you regarding the clinical study; so it's about norovirus once more — assuming you got positive results out of the Phase 2 studies, at what point would the end-of-Phase 2 meeting with the FDA happen? And how do you see the timeline for designing a Phase 3 trial and getting it started? James?

James Cummings

executive
#32

Appreciate it. Assuming the Phase 2 studies deliver favorable results, our expectation is that an end-of-Phase 2 Meeting would take place in 2024, which is next year. It's possible the Phase 3 trial gets underway as soon as next year too, and we'll do that in concert with guidance from the agency. Over.

Brant Biehn

executive
#33

Great, thanks James. Andrei, I’ll direct this question to you, and it’s really about funding. What does the outlook look like for government funding in the U.S. and internationally, whether that comes from the U.K., BARDA, or other sources? Andrei, I’ll hand it over to you.

Andrei Floroiu

analyst
#34

Honestly, that's a tough one to respond to, especially at this moment, since we see that the focus and interest of different governments and government bodies have moved elsewhere. Because of that, forecasting what governments will actually do is not easy. We're still talking with key agencies, in the U.S. as well as overseas, and our view hasn't changed: our oral pill vaccine platform might have a transformative part to play in the broader fight against pandemics. So once more, those conversations are ongoing, yet predicting how things will turn out is difficult.

Brant Biehn

executive
#35

Thanks, Andrei. Phil, here's one more for you about the share price. Since several of them are basically the same, I'll just take one, but many people are asking about this identical issue. To push the shares above $1, would a reverse split happen? And if it does, what ratio would be used? Phil, I'll let you take that.

Phil Lee

executive
#36

Absolutely, Brent. We think there are major catalysts that could genuinely spark more potential interest in where our share price goes over the coming two quarters. As we said earlier during this call, those expenses do cover a top line data readout from our Phase 2 dose-ranging study, along with top line data from our Phase 2 challenge study for norovirus. As for a reverse split, our view is that one isn't necessary right now.

Brant Biehn

executive
#37

Great. Thanks, Phil. That brings our Q&A portion to a close for now. Ms. Terry, I'll turn things over to you.

Operator

operator
#38

Thanks so much. That brings today's call to a close. At this point, feel free to drop off your lines. And we appreciate you taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.